Use of LHRH-antagonists in doses that do not cause castration for the improvement of T-cell mediated immunity

摘要

The invention concerns the use of appropriate doses of an LHRH-antagonist to lower sex hormone levels resulting in a modification of the T-cell population in an individual suffering from a disease that will respond favourably to such modification. A preferred LHRH-antagonist is cetrorelix.